Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor by Sahu, Ravi P. et al.
Chemotherapeutic agents subvert tumor immunity by generating 
agonists of platelet-activating factor
Ravi P. Sahu1,2,*, Jesus A. Ocana1,3,*, Kathleen A. Harrison5, Matheus Ferracini1, 
Christopher E. Touloukian4, Mohammed Al-Hassani1, Louis Sun1, Mathew Loesch1, Robert 
C. Murphy5, Sandra K. Althouse6, Susan M. Perkins6, Paul J. Speicher7, Douglas S. Tyler7, 
Raymond L. Konger1,2, and Jeffrey B. Travers1,3,8,9
1Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN
2Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 
Indianapolis, IN
3Department of Pharmacology and Toxicology, Indiana University School of Medicine, 
Indianapolis, IN
4Department of Surgery, Indiana University School of Medicine, Indianapolis, IN
5Department of Pharmacology, University of Colorado Health Sciences Center, Aurora CO
6Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN
7The Department of Surgery, Duke University Medical Center, Durham, NC
8The Richard L. Roudebush V.A. Medical Center, Indianapolis, IN 46202
Abstract
Oxidative stress suppresses host immunity by generating oxidized lipid agonists of the platelet-
activating factor receptor (PAF-R). Because many classical chemotherapeutic drugs induce 
reactive oxygen species (ROS), we investigated whether these drugs might subvert host immunity 
by activating PAF-R. Here we show that PAF-R agonists are produced in melanoma cells by 
chemotherapy that is administered in vitro, in vivo or in human subjects. Structural 
characterization of the PAF-R agonists induced revealed multiple oxidized 
glycerophosphocholines that are generated non-enzymatically. In a murine model of melanoma, 
chemotherapeutic administration could augment tumor growth by a PAF-R-dependent process that 
could be blocked by treatment with antioxidants or cyclooxygenase-2 inhibitors or by depletion of 
regulatory T cells. Our findings reveal how PAF-R agonists induced by chemotherapy treatment 
can promote treatment failure. Further, they offer new insights into how to improve the efficacy of 
chemotherapy by blocking its heretofore unknown impact on PAF-R activation.
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INTRODUCTION
Though not the most common type of skin cancer, malignant melanoma is one of the most 
lethal (1). The American Cancer Society estimates over 76,000 new patients were diagnosed 
with melanoma of the skin, and 9480 died from malignant melanoma in 2013 
(www.cancer.org/statistics). The treatment for early stage (non-metastatic) melanoma is 
surgical excision. The treatment of metastatic melanoma is unsatisfactory as this tumor type 
is relatively resistant to chemotherapy or radiotherapy, possibly in part through cellular 
resistance to these agents (2,3). However, regional chemotherapy such as isolated limb 
chemoperfusion (ILP) with high-dose melphalan (10 times more than standard 
chemotherapy) for localized disease has proven efficacious, with complete responses in up 
to 50% and overall response rates approaching 90% (4–6). Yet, most of these responses are 
short-lived. Immunotherapy strategies appear to have the most promise for cure as the 
immune response is critical for the eradication of this tumor type (7,8).
Chemotherapeutic agents are designed to selectively kill tumor cells, and spare their non-
neoplastic counterparts. Several targets for chemotherapeutic agents exist, including DNA 
and/or DNA replication/repair machinery (9). One of the consequences of many 
chemotherapeutic agents is the generation of reactive oxygen species (ROS) (10–13). 
Several groups have demonstrated suppression of host immunity in the presence of various 
pro-oxidative stressors through a mechanism involving platelet-activating factor (1-alkyl-2-
acetyl-glycerophosphocholine; PAF). Pro-oxidative stressors including aromatic 
hydrocarbons found in jet fuel, cigarette smoke, and ultraviolet B radiation (UVB) (14–18) 
generate ROS that can act directly on glycerophosphocholines (GPC) to produce oxidized 
GPC (Ox-GPC) which are potent PAF-receptor (PAF-R) agonists (18–21). Structural studies 
using mass spectrometry have identified more than a dozen Ox-GPC, including native PAF 
itself (20–24). There is evidence for hundreds of these biologically active compounds (22–
25) that have by-passed the tightly controlled enzymatic process of PAF production (26,27). 
Like native PAF, these Ox-GPC are metabolically unstable and their half-lives in tissue/
blood are measured in minutes (27,28).
In addition to the ability of pro-oxidative stressors (e.g., UVB) or exogenous PAF-R 
agonists to inhibit host immunity as measured by contact hypersensitivity (CHS) responses 
to either chemical antigens such as 2, 4-dinitrofluorobenzene (DNFB) or delayed type 
hypersensitivity responses to antigens such as Candida albicans (14–18,29), recent studies 
have indicated that systemic PAF-R activation can augment experimental tumor growth in a 
process involving the cytokine IL-10 and Tregs (30). PAF-R antagonists have also been 
demonstrated to protect against UVB-mediated photocarcinogenesis in mice (31). PAF-
mediated systemic immunosuppression involves interleukin 10 (IL-10) and 
cyclooxygenase-2 (COX-2)-generated eicosanoids with mast cells and regulatory T cells 
(Tregs) as effectors.
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Since chemotherapeutic agents can induce ROS, the present studies were designed to test 
whether chemotherapeutic agents can generate PAF-R agonists as well as their structural 
characterization. Finally, these studies sought to define whether ROS-generated PAF-R 
agonists impact chemotherapy effectiveness. These studies provide the first evidence that 
chemotherapeutic agents induce systemic immunosuppression via systemic PAF-R signaling 
in a process that can be ameliorated via antioxidants and COX-2 inhibitors.
MATERIALS AND METHODS
Reagents and cell lines
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless indicated 
otherwise. B16F10 and SK23MEL cells obtained from ATCC (Boston, MA) were grown in 
DMEM high glucose with 10%FCS as previously described (30). Cell lines were grown to 
approximately 80–90% confluence in 10 cm dishes, and washed three times with Hanks 
Balanced Salt Solution (HBSS) and then incubated with 2 ml of pre-warmed (37 °C) HBSS 
with 10mg/ml fatty acid-free BSA with 2 µM of the serine hydrolase inhibitor pefabloc. In 
some experiments, antioxidants were preincubated for 60 min before addition of 
chemotherapeutic agents or DMSO (0.5%) vehicle. The incubations were quenched by 
addition of 2 ml of ice-cold methanol followed by methylene chloride, and lipids extracted 
as described (17,18,20).
Mice—Female C57BL/6-wild type mice (PAF-R expressing; age 6–8 week) were 
purchased from The Charles River Laboratories. Age-matched female PAF-R-deficient 
(Ptafr−/−) mice on a C57BL/6 background, generated as described previously (32), were a 
kind gift of Professor Takao Shimizu (University of Tokyo Department of Biochemistry). 
FoxP3-EGFP reporter mice (33) obtained from JAX, and FoxP3EGFP mice crossed with 
Ptafr−/− mice were used in some experiments. It should be noted that similar effects were 
noted between Ptafr−/− and Ptafr−/− Foxp3EGFP mice. Immunodeficient NOD.CB17-
PrkdcSCID/J (Common name: NOD SCID) mice were purchased from the Indiana 
University Simon Cancer Center Core facility. In some experiments mice were fed with 
vitamin C-enriched (10g/kg; Research Diets, Inc., New Brunswick, NJ) and 5 mM N-
acetylcysteine (NAC) in water ad libitum for 10 days prior to intratumoral chemotherapy 
injection of tumor and until the termination of the experiment as per our previous studies 
(17,30). All mice were housed under specific pathogen-free conditions at the Indiana 
University School of Medicine. All procedures were approved by the Animal Care and Use 
Committee of Indiana University School of Medicine.
Measurement of PAF-R agonists
Calcium mobilization studies—The presence of systemic PAF-R agonists in lipid 
extracts derived from the chemotherapeutic agent-treated tumors/cell lines was measured by 
the ability of the lipid extracts to induce an intracellular Ca2+ mobilization response in PAF-
R expressing KBP cells, but not in KBM cells lacking the PAF-R, as previously described 
(17,34). In brief, KBP and KBM cells were preloaded with the Ca2+-sensitive indicator, 
fura-2-AM (4 µM in Hanks' balanced salt solution without dye) at 37°C for 90 min, washed 
and resuspended in Hanks' balanced salt solution at room temperature before use. Lipid 
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extracts from cells or weighed tumors obtained from groups of chemotherapy vs vehicle 
treated cells/tumors untreated (sham) exposed mice were added to an aliquot of these cells 
(1.0–1.5 × 106 cells/2 ml) in a cuvette at 37°C with constant stirring. The lipid extracts were 
normalized to cell number or mg wet tissue weight or 1/10th volume of perfusate. CPAF and 
endothelin-1 (ET-1) dissolved in ethanol (adjusted to 1µM) were used as positive controls. 
Fura-2-AM fluorescence was monitored in a Hitachi F-4010 spectrophotometer with 
excitation and emission wavelengths of 331 and 410 nm, respectively. The Ca2+ influx in 
suspensions was calculated as described (17,18,34) and shown as percentage of maximal 
peak calcium flux induced by either CPAF or ET-1.
Mass Spectrometry studies—Mass spectrometry was performed on cell lines and 
perfusion samples using the AB Sciex (Foster City, CA) triple quadrupole QTRAP® 5500 
mass spectrometer, equipped with a CTC-PAL autosampler and a Shimadzu HPLC as 
previously described (24). Please see on-line Supplemental Methods for details of 
instrument settings and characterization of the various species monitored.
In vivo tumor growth studies—To determine the ability of intratumoral chemotherapy 
to modulate melanoma tumor growth, 0.5×106 B16F10 cells which lack functional PAF-R 
(30), were implanted subcutaneously into both shaved hind flanks of WT and Ptafr−/− mice 
to produce two tumors. Tumor growth (length and width) was monitored and measured at 
various times with digital calipers (Mitituyo), and tumor volume was calculated (major 
length × minor length2/2). On day 6 of tumor implantation and every three days afterwards, 
the left flank tumor was injected with 100 µl of either etoposide (36 mg/kg), melphalan (15 
mg/kg), or PBS with 0.5% DMSO vehicle. The working dose of etoposide and melphalan 
was achieved by performing dose-dependent pilot studies in WT mice (n=3–5). To define 
the ability of COX-2 inhibitors to modulate the effects of chemotherapy, SC-236 (200 ng), 
NS-398 (5 µg), or 100ul PBS with 0.5% DMSO vehicle were injected i.p. at day 0 and every 
3 days afterwards.
Human regional chemotherapy studies—Subjects undergoing regional chemotherapy 
with melphalan for melanoma were recruited for these studies. During the procedure, 8 ml 
of perfusate was removed at various times (after establishment of the perfusion, once the 
core limb temperature was 40 °C, and 15, 30, 45 and 60 min following melphalan treatment) 
from the circuit and placed into equal volumes of ice-cold methanol and methylene chloride, 
and lipids extracted. The human studies were approved by the Indiana University’s and 
Duke University’s School of Medicine Institutional Review Boards.
Statistical analysis—For all murine studies, individual experiments were performed 
using at least 4 mice per experimental group and repeated as necessary (at least once) to 
verify reproducibility and provide additional data for analysis. All statistical calculations 
were performed using SAS Version 9.3. Tumor volume was calculated as (major × minor2)/
2.For the mice studies, the analysis focused on the end of the study, specifically on Days 14–
18, where available. The normality of data and equal variances were checked by Shapiro-
Wilk’s and Levene’s tests and was a reasonable assumption in all cases. For the mice data 
and in vitro data, we used equal or unequal variance t-tests to compare two groups. For 
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comparing more than two groups, we used analysis of variance (with the Welch 
approximation if the variances were unequal) and post hoc Tukey-adjusted pair-wise tests. 
The data represent mean values with SE. Differences were considered statistically 
significant when the P value was less than 0.05 and marginally significant when the P value 
was less than 0.10.
RESULTS
Chemotherapeutic agents generate PAF-R agonists in a process blocked by antioxidants
The first studies were designed to test whether chemotherapeutic agents can induce PAF-R 
agonists in melanoma cells. As multiple glycerophosphocholine species can act as PAF-R 
agonists, we quantified total PAF-R biochemical activity as measured by intracellular 
calcium mobilization responses in Fura-2-loaded PAF-R-expressing KBP cells (34) 
compared to excess (1 µM) of the metabolically stable PAF-R agonist carbamoyl-PAF 
(CPAF) in lipid extracts from murine B16F10 cells following treatment with the diverse 
agents etoposide, cisplatin or melphalan. Note that the amount of total PAF-R agonistic 
activity is defined as the Ca2+ mobilization peak height of the normalized lipid extract as a 
% of the peak height from excess CPAF (1 µM) response (17,18,34). Use of this 
semiquantitative biochemical assay allows all PAF-R activity to be measured. As shown in 
Fig. 1a, lipid extracts from B16F10 melanoma cells treated with chemotherapeutic agents 
induced PAF-R agonistic activity only in PAF-R-expressing KBP but not in PAF-R-negative 
KBM cells. Moreover, treatment of KBP but not KBM with these lipid extracts derived from 
chemotherapeutic agent-treated B16F10 cells resulted in the release of IL-8 in the 
supernatants using our published (18) methodology (data not shown). Time course studies 
revealed that chemotherapeutic agents triggered PAF agonistic activity in murine B16F10 
cells that were similar to human SK23MEL cells (Fig. 1b and Supplementary Fig. S1). 
Murine B16F10 melanoma cells do not express functional PAF-Rs as measured by lack of 
Ca2+ response to CPAF, and lack of PAF-R mRNA by qPCR (39). To define whether the 
presence of the PAF-R (which has been reported to be expressed on many human 
melanomas (35)) can modulate chemotherapy-induced PAF agonistic activity, we 
transduced B16F10 cells with the PAF-R gene construct using MSCV2.1 retrovirus, 
generating B16F10PAF-R (PAF-R-expressing;B16P) and B16F10MSCV2.1 (control PAF-
R-negative; B16M) cells (see ref 30 for characterization of these cell lines). 
Chemotherapeutic agent treatment resulted in significantly more PAF-R agonistic activity in 
the PAF-R-expressing B16P cells (Fig. 1c). Similar to our previously published findings 
examining PAF-R biochemical activity generated in human epithelial tumor cells or human 
skin in response to the pro-oxidative stressor UVB (20,24,36), preincubation of melanoma 
cells with antioxidants vitamin C or N-acetylcysteine (NAC) blocked this PAF agonistic 
activity (Fig. 1d).
Mass spectrometry-based structural studies using deuterium-labeled internal standards 
revealed that there were significantly increased levels of not only native PAF, but also Ox-
GPC PAF-R agonists produced non-enzymatically in B16F10 cells in response to etoposide 
treatment (Fig. 2). Levels of a large number of individual Ox-GPC were increased 2–3 fold 
over baseline, but no consistent changes in lyso-GPC species were noted (data not shown). 
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The actual amounts, structures and methods used to measure the Ox-GPCs are shown in 
Supplementary Table I and the supplementary online methods. These studies indicate that 
chemotherapeutic agents can trigger the generation of Ox-GPCs with PAF-R activity in 
murine and human melanoma cells in vitro.
Intratumoral injection of chemotherapeutic agents generates PAF-R agonists
Though not commonly used, intratumoral injection of chemotherapeutic agents is a viable 
treatment for localized disease (37,38). To define whether chemotherapeutic agents can 
induce the production of PAF-R agonists in vivo, B16F10 tumors were implanted into 
syngeneic C57BL/6 murine hosts or human SK23MEL tumors implanted into 
immunodeficient SCID mice. When the tumors were approximately 10 mm in diameter, 
they were injected with either etoposide or melphalan or PBS vehicle control. Tumors were 
removed one hour post-injection, weighed, and lipids extracted and PAF-R biochemical 
activity assayed. Intratumoral injections of chemotherapy agents but not PBS vehicle 
resulted in the production of PAF-R agonists in both murine B16F10 and human SK23MEL 
tumors (Fig. 3). Of interest, injection of chemotherapeutic agents directly into skin without 
tumors did not result in the generation of significant levels of PAF-R agonistic activity (data 
not shown).
To assess the ability of antioxidants treatment to modulate chemotherapy-generated PAF-R 
agonists in vivo, C57BL/6 mice were fed with vitamin C-enriched chow and 5 mM NAC in 
water ad libitum for 10 days before tumor implantation and continued on antioxidant diet 
until the termination of the experiment. Tumors were treated with either etoposide, 
melphalan, or vehicle and PAF-R agonist activity determined from lipid extracts of 1 hour 
treated tumors. This antioxidant regimen, which we have previously demonstrated blocks 
both the inhibition of CHS and augmentation of tumor growth induced by UVB treatment 
(17,30) results in the decreased formation of PAF-R agonists by chemotherapy (Fig. 3a). 
These studies indicate that chemotherapeutic agents can generate PAF-R agonists in vivo, in 
a process partially blocked by antioxidants.
PAF-R activation diminishes experimental chemotherapy effectiveness via Tregs in a 
COX-2-dependent process
Given our findings that intratumoral chemotherapy generates PAF-R agonists in vivo and 
that systemic PAF-R activation augments experimental tumor growth via 
immunosuppression (30), we assessed whether intratumoral chemotherapy could generate 
enough PAF-R agonists to modulate tumor growth. Our protocol was modified in that WT 
and PAF-R-deficient (Ptafr−/−, PAFR-KO) mice underwent implantation with B16F10 
tumors on both dorsal hindquarters (2 tumors/mouse). The left flanktumors were treated 
with intratumoral chemotherapy or PBS vehicle control starting at day 6 of tumor cell 
implantation and repeated every 3 days until the termination of the experiment, while the 
other (right flank) tumors were left undisturbed. Intratumoral chemotherapy of one tumor 
with melphalan (15 mg/kg) or etoposide (36 mg/kg) resulted in an enhanced growth of the 
second (undisturbed) tumor in PAF-R-positive WT compared with Ptafr−/− hosts (Fig. 4a–
c). Though intratumoral chemotherapy resulted in growth inhibition of the chemotherapy-
treated left flank tumors, loss of host PAF-R function exerted no perceptible effect on the 
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left flank tumor growth characteristics (Supplementary Fig S2). Subjecting mice to 
antioxidant treatment had no effects on the untreated right flank tumor growth by itself, yet 
inhibited the melphalan-mediated augmentation of growth of the second tumor (Fig. 4d). 
Antioxidant diet also blocked etoposide-mediated augmentation of right flank tumor growth 
(Supplementary Fig. S3a). Importantly, antioxidant diet had no effect on the growth of right 
flank tumors in chemotherapy-treated PAF-R-deficient hosts (Supplementary Fig. S3). Of 
note, we did not detect differences in the growth of the chemotherapy-treated left flank 
tumors when WT or Ptafr−/− mice were placed on an antioxidant diet. Overall, these 
findings fit with the concept that chemotherapeutic agents generate Ox-GPCs via ROS 
which then inhibit tumor immunity resulting in an augmentation of tumor growth in a PAF-
R-dependent manner.
Previous reports have demonstrated that PAF-R-mediated inhibition of CHS is blocked by 
COX-2 inhibitors (14–18). To assess whether COX-2 is crucial for PAF-R mediated 
augmentation of experimental tumor growth, WT and Ptafr−/− mice were implanted with a 
single B16F10 tumor and then treated with COX-2 inhibitors (SC-236 & NS-398) alone or 
along with systemic CPAF. COX-2 inhibitors alone did not affect tumor growth, yet blocked 
CPAF-mediated augmentation of B16F10 tumor growth in WT mice (Fig. 5a,b) but had no 
effect on Ptafr−/− hosts (Supplementary Fig. S4). Pharmacologic inhibition of COX-2 also 
blocked the augmentation of tumor growth associated with chemotherapy (Fig. 5c for 
melphalan and Supplementary Fig. S5 for etoposide). These studies indicate that 
chemotherapy-generated PAF-R agonists augment experimental tumor growth in a process 
inhibited by antioxidants and COX-2 inhibitors.
PAF-R-dependent inhibition of CHS reactions is due to an increase in Tregs (18). Our 
previous studies have also demonstrated that Tregs are necessary for UVB-mediated 
augmentation of B16F10 tumor growth (30). The next studies were designed to define the 
role of Tregs in chemotherapy-mediated augmentation of experimental tumor growth. Use 
of a Treg-depleting strategy (anti-CD25 antibodies) which we have previously reported 
blocked UVB-mediated upregulation of tumoral Tregs (30) inhibited the chemotherapy-
mediated augmentation of second tumor growth (Fig. 5d). Using Foxp3EGFP reporter 
transgenic mice we measured increased numbers of Tregs in tumors in response to systemic 
PAF-R activation which was blocked by COX-2 inhibition (Supplementary Fig. S6). These 
studies demonstrate that systemic PAF-R-mediated augmentation of tumor growth is 
dependent upon Tregs and suggest that COX-2 is necessary for their formation.
Identification of PAF-R agonists produced in response to chemotherapy in humans
To test whether chemotherapy exposure results in the production of PAF-R agonists in 
humans, 8 ml aliquots of perfusate were removed at various times from human subjects 
undergoing regional chemotherapy for melanoma. In this procedure, the major artery and 
vein of an affected extremity is cannulated and blood along with melphalan is perfused for 
30–60 minutes in the heated (40 °C) limb (39). Minimal amounts of PAF-R agonists were 
found in the circulating perfusate before addition of the melphalan (Fig. 6a). However, once 
the melphalan chemotherapy began perfusing in the heated limb, significant amounts of 
PAF-R agonistic activity was measured in the perfusates, with the highest amounts found at 
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the conclusion of regional chemotherapy treatment. Structural characterization of perfusates 
using mass spectrometry identified PAF and several Ox-GPC species (Fig. 6b). These 
studies indicate that chemotherapy exposure generates systemic PAF-R agonists in humans.
DISCUSSION
Chemotherapy is the most commonly used medical treatment for cancer. The present studies 
describe a previously unappreciated mechanism by which chemotherapy exposure results in 
the production of PAF-R agonists which are known to inhibit tumor immunity (30). These 
data support the model that Ox-GPC PAF-R agonists produced in part due to ROS from 
chemotherapeutic agents can exert systemic immunosuppressive effects. That 
chemotherapeutic agent-triggered PAF-R agonist formation and augmentation of tumor 
growth are partially inhibited by antioxidants suggests that antioxidants could have potential 
use in chemotherapy protocols. Of interest, systemic antioxidants have been championed for 
adjuvant use along with chemotherapy to decrease therapy side effects (40,41). Yet, use of 
antioxidants along with chemotherapy is considered controversial due to concerns about 
possible interference with chemotherapeutic agent-mediated direct killing of tumor cells 
(42,43). It should be noted that the present studies indicate that antioxidant treatment alone 
or in chemotherapy-treated PAF-R-deficient mice did not have any perceptible effects on 
tumor growth.
Oxidation of esterified fatty acyl residues introduces oxy functions, rearranges bonds and 
fragments carbon-carbon bonds by β-scission that generate a myriad of phospholipid 
reaction products including PAF-R agonists (19–25). In contrast to the tightly controlled 
enzymatic pathways for PAF biosynthesis, large amounts of numerous Ox-GPC PAF-R 
agonists can be produced non-enzymatically. The present studies not only demonstrate that 
chemotherapy-generated PAF-R agonistic activity is diminished by antioxidants, but 
structural characterization of this activity reveals Ox-GPCs known to be produced non-
enzymatically. Consistent with the notion that chemotherapy is a potent pro-oxidative 
stressor, intratumoral injection of melphalan resulted in increased urine levels of 
immunoreactive 8-isoprostane (8-iso Prostaglandin F2α), an eicosanoid formed from free 
radical-catalyzed peroxidation of arachidonate, which was blunted in mice fed antioxidant 
diet (data not shown). It is likely that tumor cellular membranes serve as the source of 
oxidized phospholipids from the chemotherapeutic agent intratumoral injections and are thus 
the source of chemotherapy-mediated PAF-R agonist formation in the experimental murine 
models used. However, it is not clear whether the source of PAF-R agonists produced during 
human regional chemotherapy is derived from the tumors, or from normal tissue.
The present studies demonstrate that high levels of PAF-R agonist activity are measured 
during regional chemotherapy. In contrast to the poor responsiveness of metastatic 
melanoma to standard chemotherapy, regional chemotherapy appears to be one of the most 
successful anti-melanoma therapies as measured by percentage of clinical responders (4–6). 
Hyperthermic isolated limb perfusion, first reported in 1958, allows the regional delivery of 
chemotherapeutic agents (commonly melphalan) to patients with in-transit metastases 
localized to extremities which would not be approachable by surgical resection. The ability 
to use 10-fold higher than the standard chemotherapy doses along with heat provides a very 
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potent combination to kill tumor cells. Another advantage of regional chemotherapy is the 
ability to treat the entire area at highest risk of reoccurrence by eliminating clinically occult 
microscopic tumor disease with minimal risk of systemic toxicity. We hypothesize that this 
combination of heat and high-dose melphalan also allows a rather unique environment that 
promotes ROS. Though it is possible that standard doses of systemic chemotherapy could 
generate immunosuppressive Ox-GPC PAF-R agonists which impede therapy effectiveness, 
this novel and previously unappreciated pathway would more likely play an important role 
in regional chemotherapy.
Tumoral resistance to chemotherapy is an important clinical problem and is an area of active 
study. In contrast to cellular resistance to the effects of chemotherapy, the present studies 
describe a novel mechanism by which chemotherapeutic agents can subvert anti-tumor 
immunity. Indeed, our previous studies using UVB irradiation of skin as the source for PAF-
R agonists provide several lines of evidence implicating anti-tumor immunity, in particular 
Tregs in the PAF-mediated effects on experimental B16F10 tumor growth (30). First, PAF 
effects are not seen when tumors are placed in immunodeficient murine hosts. Second, use 
of PAF-R-negative B16F10 cells transduced with functional PAF-Rs implanted in WT vs 
Ptafr−/− hosts have confirmed that the PAF-R mediating the response is on the host, not 
tumor. Finally, use of neutralizing antibodies against IL-10 or depleting Tregs both block 
PAF-mediated augmentation of experimental tumor growth. It is possible that this 
previously unappreciated pathway could provide an explanation for why immunotherapy 
strategies tend to be more effective when given to patients who have not received prior 
chemotherapy, which according to our model could potentially tolerize the immune system 
to the tumors (44–46).
Exogenous pro-oxidative stressors ranging from aromatic hydrocarbons to cigarette smoke 
to UVB radiation have been shown to induce systemic immunosuppression via PAF-R 
signaling which is blocked by antioxidants (16–18). Apoptotic cells generate PAF and also 
contribute to melanoma tumor progression via PAF-R activation (47). The production of 
PAF-R agonists from these various agents begins a cascade of events leading to systemic 
immunosuppression. The cytokines which appear to be critical for the immunosuppression 
include IL-10 and COX-2-generated eicosanoids (14,15,18). Mast cells and regulatory T 
cells are also implicated in PAF-R-dependent systemic immunosuppression (18,30,48). The 
present studies demonstrating that COX-2 inhibitors block chemotherapy-mediated 
augmentation of experimental tumor growth are not only consistent with previous studies 
characterizing the role of this eicosanoid-generating enzyme in PAF-mediated systemic 
immunosuppression (14,15,18), they also provide the rationale for future studies testing the 
ability of COX-2 inhibitors to enhance the effectiveness of regional chemotherapy. It should 
be noted that COX-2 inhibition has been shown to exert not only protective properties on the 
host, but also direct antitumor effects in a variety of tumor types (49,50). In contrast, 
antioxidant use along with chemotherapy is associated with controversy due to possible 
concerns that these agents could interfere with the efficacy of chemotherapy (42,43).
In summary, the present studies provide the first evidence that PAF-R signaling can inhibit 
chemotherapy effectiveness. In contrast to chemotherapy resistance that is applicable at the 
tumor cell level, this process is due to the subversion of host tumor immunity. That 
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chemotherapy generates PAF-R agonists in humans is suggestive that this novel pathway 
could have tremendous clinical significance. Since this process involves the pro-oxidative 
qualities of chemotherapeutic agents and is neutralized by antioxidants, with downstream 
effects susceptible to COX-2 inhibition, these studies could provide the impetus for future 
studies to define the clinical significance of this novel pathway in humans.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations used in this paper
CHS contact hypersensitivity
COX-2 cyclooxygenase type 2
CPAF 1-hexadecyl-2-N-methylcarbamoyl glycerophosphocholine
DNFB dinitrofluorobenzene
GPC glycerophosphocholine
Ox-GPC oxidized GPC
IL-10 interleukin 10
NAC N-acetylcysteine
PAF platelet-activating factor
PAF-R PAF receptor
PAF-AH PAF acetylhydrolase
ROS reactive oxygen species
Treg regulatory T cells
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Figure 1. Chemotherapy agents generate PAF-R agonist formation in melanoma cells
A). Examples of PAF-R Ca2+ biochemical assays. PAF-R-expressing KBP or PAF-R-
negative KBM cells were loaded with Fura-2 AM, and treated with lipid extracts derived 
from 5 × 106 B16F10 cells treated with 100 µg/ml etoposide or DMSO vehicle for 1 h, and 
intracellular Ca2+ levels monitored over time. Excess (1 µM CPAF or endothelin-1 [ET-1]) 
was added at the end of the assay to allow quantitation of the Ca2+ response. B). Time 
course of chemotherapy-generated PAF-R activity. Lipid extracts were obtained from 5 × 
106 B16F10 cells treated with 100 µg/ml of chemotherapeutic agents, or 0.5% DMSO 
vehicle for various times, and tested for total PAF-R agonistic activity using PAF-R-positive 
Sahu et al. Page 14
Cancer Res. Author manuscript; available in PMC 2015 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
KBP cells loaded with the calcium-specific dye Fura-2. The data are the Mean ± SE 
percentage of peak intracellular calcium response as a percentage of that induced by 1 µM 
CPAF from at least four separate experiments. C). Dose-responsiveness of chemotherapy-
generated PAF-R agonists in PAF-R-negative vs B16F10 cells expressing PAF-Rs. Lipid 
extracts were obtained from PAF-R-expressing B16F10PAF-R (B16P) or control 
B16F10MSCV2.1 (B16M) cells treated with various doses of chemotherapeutic agents for 1 
h, and tested for PAF-R agonistic activity as above. The data are the mean ± SE percentage 
of peak intracellular calcium response (normalized to CPAF) from 3–4 separate 
experiments. D). Chemotherapy agent-stimulated PAF-R agonist formation is inhibited by 
antioxidants. Lipid extracts were obtained from B16P and B16M cells preincubated for 1 h 
with antioxidants vitamin C (2.5 mM), NAC (5 mM), or 0.5% DMSO vehicle prior to a 1 h 
treatment with 100 µg/ml chemotherapeutic agents, and tested for total PAF-R agonistic 
activity. The data are the mean ± SE percentage of peak intracellular calcium response 
(normalized to CPAF) from at least three separate experiments. * Denotes statistically 
significant (P <0.05) changes in levels of PAF-R agonist activity from control values for 
figures (B) and (C), and differences between chemotherapy-treated B16P and B16M cells in 
(D). For (C) the significant changes were for cisplatin at 10 µg/ml and for cisplatin, and 
etoposide at 100 µg/ml vs 0 dose.
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Figure 2. Structural characterization of chemotherapy-generated PAF-R agonists
B16F10 cells were treated with 100 µg/ml of etoposide, or 0.5% DMSO vehicle for two 
hours. Lipid extracts were analyzed by HPLC/MS/MS using deuterium-labeled internal 
standards to quantify PAF and Ox-GPC species. The data are expressed as mean ± SE fold 
increase of etoposide over vehicle-treated from 5 separate experiments. Please see 
Supplementary Table I for structures and exact values for the GPC species. * Denotes 
statistically significant (P < 0.05) changes from vehicle-treated.
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Figure 3. Intratumoral chemotherapy generates PAF-R agonist formation in vivo
Lipid extracts were obtained from A). Murine B16F10 tumors implanted on WT mice fed 10 
mg/kg vitamin C-enriched chow + 5 mM NAC in water ad libitum or standard diet/water for 
10 days before tumor implantation or B) Human SK23MEL tumors implanted onto SCID 
mice fed standard diet, one hour following intratumoral injection with either 36mg/kg 
etoposide or 15mg/kg melphalan or 100 µl PBS vehicle, normalized to wet tumor weight (10 
mg), and were tested for PAF-R agonistic activity as in Fig. 1. The data are the mean ± SE 
percentage of peak intracellular calcium response (normalized to CPAF) from 4–6 separate 
tumors. *Denotes statistically significant (P < 0.05) changes in levels of PAF-R agonists in 
comparison to vehicle-treated.
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Figure 4. Intratumoral chemotherapy treatment augments the growth of untreated B16F10 
melanomas in a PAF-R-dependent manner
WT and PAFR-KO (Ptafr−/−) mice were implanted with B16F10 tumors on both the dorsal 
hind flanks. Six days later (and q 3days afterwards) one of the tumors (on the left side) was 
treated with A, B). 15 mg/kg melphalan (n=6–7), C). 36 mg/kg etoposide (n=9–12), or 
vehicle (n=5–6), and the other tumor (on the right side) left undisturbed. The data depicted 
are the mean ± SE of tumor volume of untreated tumors over time. B). Data represent the 
volume of untreated tumors at day 17 from vehicle and melphalan-treated WT and PAFR-
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KO mice. D). Effect of antioxidants on the melphalan-mediated increased tumor growth. 
WT mice were placed on antioxidant diet as in Fig. 3 for 10 days before placement of dual 
B16F10 tumors, followed by intratumoral treatment with melphalan (n=10–11) every 3 days 
starting at day 6. The data depicted are the mean ± SE of tumor volume of untreated tumors 
over time. Between WT & PAFR-KO mice, there were no statistically significant 
differences in the growth of chemotherapy- or vehicle-injected tumors nor the growth of the 
undisturbed tumors in response to vehicle treatment of the contralateral tumors. Statistical 
significance of changes in tumor volumes denoted by **(P < 0.01) or * (P < 0.05) 
or #(P<0.1).
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Figure 5. Role of COX-2 and Tregs in chemotherapy-mediated PAF-R-dependent augmentation 
of tumor growth
A,B). COX-2 inhibitor blocks PAF-R-augmentation of tumor growth. WT mice (n=6–7) 
implanted with a single tumor were treated at day 0 and every 6 days with ip injections of 
CPAF (250 ng) or vehicle, with or without COX-2 inhibitors A) SC-236 (200 ng), B) 
NS-398 (5 µg). C). COX-2 inhibitor blocks chemotherapy-mediated augmentation of tumor 
growth. WT mice implanted with two tumors were treated with SC-236 or vehicle at day 0 
and every 3 days, and underwent intratumoral treatment with PBS vehicle (n=7) or 
melphalan (n=16) (C) every 3 days starting at day 6. Tumor growth was assessed over time 
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as in Fig 4. The data depicted are the mean ± SE of tumor volume of untreated tumors over 
time in which the contralateral tumor was treated with chemotherapeutic agent. D). 
Depleting Tregs blocks etoposide-mediated enhanced growth of secondary tumors. WT mice 
(n=7–8) were treated with isotype control (IgG1 and IgM1) or depleting antibodies against 
CD25 (clones PC61.5.3 IgG1 and 7D4 IgM1, 1 mg each) two days before dual tumor 
implantation and etoposide treatment as outlined in Fig 4. Statistical significance of changes 
in tumor volumes denoted by **(P < 0.01) or * (P < 0.05) or #(P<0.1).
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Figure 6. PAF-R agonists are generated during regional chemotherapy
A). Lipid extracts were obtained from 8 ml of perfusate drawn at various times (once the 
circuit was placed [Control], once the limb was at 40° C [Heat], or following addition of 
melphalan) from six separate subjects during isolated limb chemoperfusion and tested for 
PAF-R activity as in Figure 1. The data are the mean ± SE percentage of peak intracellular 
calcium response (normalized to 1 µM CPAF and 1/10th of blood volume) of duplicate 
samples. B). Structural characterization of Ox-GPCs in human subjects. Control and 30 min 
post chemotherapy perfusates from three subjects were subjected to mass spectrometry as 
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outlined in Fig. 2. The data depicted are mean ± SE ng of GPC per 8 ml perfusate from three 
separate subjects. * Denotes statistically significant (P < 0.05) fold changes from values 
measured in control perfusates.
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